Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bioventus Inc. (BVS : NSDQ)

• Company Description    Bioventus Inc. delivers clinically proven, cost-effective products which help people heal quickly and safely. It includes offerings for osteoarthritis, surgical and non-surgical bone healing. Bioventus Inc. is based in DURHAM, N.C. Number of Employees: 930

• Price / Volume Information    Yesterday's Closing Price: $7.45 Daily Weekly Monthly 20 Day Moving Average: 327,518 shares Shares Outstanding: 82.68 (millions) Market Capitalization: $615.96 (millions) Beta: 0.80 52 Week High: $12.61 52 Week Low: $5.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.44% 11.44% 12 Week 1.09% -3.11% Year To Date -29.05% -37.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4721 EMPEROR BOULEVARD SUITE 100 - DURHAM,NC 27703 USA ph: 919-474-6700 fax: - investor.relations@bioventus.com http://www.bioventus.com

• General Corporate Information    Officers Robert E. Claypoole - Chief Executive Officer; President and Director William A. Hawkins - Chairman Mark L. Singleton - Senior Vice President and Chief Financial Officer John A. Bartholdson - Director Patrick J. Beyer - Director Peer Information Bioventus Inc. (GSAC) Bioventus Inc. (CASI) Bioventus Inc. (ALCD.) Bioventus Inc. (OMNN) Bioventus Inc. (CGPI.) Bioventus Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 09075A108 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/10/26 Share - Related Items Shares Outstanding: 82.68 Most Recent Split Date: (:1) Beta: 0.80 Market Capitalization: $615.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.26 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/10/26

• Fundamental Ratios P/E Current FY Estimate: 28.65 Trailing 12 Months: 12.63 PEG Ratio: - Price Ratios Price/Book: 2.97 Price/Cash Flow: 6.96 Price / Sales: 1.09 EPS Growth vs. Year Ago Period: 150.00% vs. Previous Quarter: -28.57% Sales Growth vs. Year Ago Period: -0.23% vs. Previous Quarter: -6.10% ROE 09/30/25 - 26.38 06/30/25 - 23.04 03/31/25 - 21.47 ROA 09/30/25 - 7.27 06/30/25 - 6.04 03/31/25 - 5.38 Current Ratio 09/30/25 - 1.74 06/30/25 - 1.48 03/31/25 - 1.43 Quick Ratio 09/30/25 - 1.14 06/30/25 - 0.96 03/31/25 - 0.89 Operating Margin 09/30/25 - 9.12 06/30/25 - 7.75 03/31/25 - 7.06 Net Margin 09/30/25 - 1.39 06/30/25 - -0.03 03/31/25 - -5.57 Pre-Tax Margin 09/30/25 - 2.61 06/30/25 - 0.85 03/31/25 - -8.29 Book Value 09/30/25 - 2.51 06/30/25 - 2.43 03/31/25 - 2.26 Inventory Turnover 09/30/25 - 1.92 06/30/25 - 1.96 03/31/25 - 2.03 Debt-to-Equity 09/30/25 - 1.50 06/30/25 - 1.48 03/31/25 - 1.66 Debt-to-Capital 09/30/25 - 60.03 06/30/25 - 59.67 03/31/25 - 62.46

Powered by Zacks Investment Research ©